Regorafenib
- CAS No.
- 755037-03-7
- Chemical Name:
- Regorafenib
- Synonyms
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;Regorafenib (BAY 73-4506);CS-169;RG-API;CS-1930;Rigofeni;Regafenib;regorafinib;Regorafenib;BAY 73-4506
- CBNumber:
- CB32498792
- Molecular Formula:
- C21H15ClF4N4O3
- Molecular Weight:
- 482.82
- MOL File:
- 755037-03-7.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/25 20:04:51
| Melting point | 206.0 to 210.0 °C |
|---|---|
| Boiling point | 513.4±50.0 °C(Predicted) |
| Density | 1.491±0.06 g/cm3(Predicted) |
| storage temp. | Refrigerator |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 12.04±0.70(Predicted) |
| form | White powder. |
| color | Pale Pink to Light Pink |
| CAS DataBase Reference | 755037-03-7 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| HS Code | 29242990 | |||||||||
| NFPA 704 |
|
Regorafenib price More Price(2)
Regorafenib Chemical Properties,Uses,Production
Description
In September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.
Characteristics
Class: receptor tyrosine kinase
Treatment: colorectal cancer, GIST, HCC
Elimination half-life = 26-28 h
Protein binding = 99.5%
Uses
BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
Definition
ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ usly received chemotherapy, anti-EGFR or anti-VEGF therapy.
Regorafenib Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| GLR Innovations | +91 9891111994 | New Delhi, India | 4542 | 58 | Inquiry |
| Prajna generics pvt ltd | +91-9441174873 +91-9441174873 | Hyderabad, India | 24 | 58 | Inquiry |
| NATCO Pharma Limited | +91-9849511345 +91-9866005199 | Hyderabad, India | 24 | 58 | Inquiry |
| Aspen Biopharma Labs Pvt Ltd | +91-9248058660 +91-9248058662 | Telangana, India | 234 | 58 | Inquiry |
| Archerchem Healthcare Pvt., Ltd. (part of Archerchem Group) | 91-22-42361111 | Maharashtra, India | 147 | 58 | Inquiry |
| Yasham Speciality ingredients Pvt Ltd | 91-22-40639900 | Maharashtra, India | 42 | 58 | Inquiry |
| Avra Laboratories Pvt., Ltd. | 91-40-27178571 | Hyderabad, India | 15 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| Prajna Generics Private Limited | 08048250185Ext 545 | Hyderabad, India | 24 | 58 | Inquiry |
| NATCO PHARMA LIMITED | +91-40-23547532 | New Delhi, India | 24 | 58 | Inquiry |
Related articles
- Regorafenib: Uses, Mechanism of Action and Side effects
- Regorafenib is a targeted anticancer prescription drug that belongs to the diphenylurea class of multikinase inhibitors, targe....
- Mar 27，2024
- Regorafenib for the Treatment of Sarcoma
- Regorafenib shows promise in treating sarcomas by targeting multiple pathways and improving progression-free survival, with ma....
- Feb 6，2024
- Regorafenib: Applications, metabolism, pharmacokinetics and toxicity
- Regorafenib is a new oral small molecule multi-kinases inhibitor. It can inhibit the target kinases associated with angiogenes....
- Jul 17，2023
755037-03-7(Regorafenib)Related Search:
1of4
chevron_right